1. At a Glance
₹1,276 crore market cap. Stock at ₹13.7. Down 15% in 3 months. Down 21% in 6 months. Down 20% in one year.
And yet — Q3 FY26 numbers are quietly flexing.
Sales at ₹115 crore. PAT at ₹18.9 crore. Operating margin at 18%. Quarterly profit up 47% YoY. ROCE at 18.6%. ROE at 15.5%. Debt? Practically zero at ₹0.30 crore.
This is a ₹500 crore annual revenue company trading at 18.5 P/E in a pharma industry where the median PE is 28.
Now here’s the spicy part.
They just expanded injectable capacity. They bought Mumbai property worth ₹51.7 crore. They amended MOA to enter power, nutraceuticals and real estate. They installed a 435KW solar rooftop plant.
Pharma company? Real estate company? Solar company? Or Bankda family empire expansion vehicle?
Let’s investigate.
2. Introduction – The Curious Case of a ₹13 Stock Making ₹19 Crore a Quarter
Established in 1995, Syncom Formulations is one of those companies that quietly built a 500+ product portfolio across tablets, injectables, capsules, liquids and more.
They operate in 25 countries. They have 400+ product registrations. They run two major divisions:
- International (35%)
- Domestic under CRATUS (35%)
Plus trading and rental income.
Now pause.
At ₹13.7 stock price, many investors scroll past it thinking “penny pharma.” But this is not some zero-revenue operator. This is a ₹501 crore TTM sales company generating ₹69 crore TTM PAT.
Profit CAGR over 3 years? 35%.
TTM profit growth? 81%.
But then why is the stock negative 20% in one year?
Working capital days increased.
No dividend payout.
Frequent regulatory fines.
Management reshuffle.
MOA amendments expanding business scope.
Is this growth story maturing — or getting distracted?
Let’s decode.
3. Business Model – WTF Do They Even Do?
Syncom manufactures 500+ pharmaceutical formulations in:
- Tablets (48% revenue)
- Injectables (17%)
- Capsules (4%)
- Liquids (3%)
- Ointments (2%)
- Others (25%)
That “Others” bucket is suspiciously large. 25% is not small change.
They operate from Pithampur, Madhya Pradesh. Injectable capacity expanded from 2 crore to 3 crore units annually. Tablet department modernized at ₹40 crore capex.
So core pharma business is solid.
But
